Related Experiment Video
Updated: Aug 5, 2026
Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
Published on: March 6, 2018
A retrospective study comparing holmium Laser enucleation vs. transurethral resection for the treatment of benign
Zhikai Dong1, Dongkai Wu1, Zhongjie Tao2
1Department of Urology, Dongyang People's Hospital, Jinhua, Zhejiang, China.
Objective:
Benign prostatic hyperplasia (BPH) is a common condition in aging men that significantly impacts quality of life. This study aimed to compare the perioperative outcomes and short-term efficacy of holmium laser enucleation of the prostate (HoLEP) vs. transurethral resection of the prostate (TURP) in patients with symptomatic BPH.
Methods:
We retrospectively analyzed data from 176 patients who underwent surgical treatment for BPH at our institution between January 2019 and December 2024. Patients were divided into two groups: HoLEP (n = 92) and TURP (n = 84). Baseline characteristics, operative parameters, postoperative complications, and functional outcomes in 6-month after surgery were compared between the groups.
Results:
Baseline demographics and prostate volume were similar between the two groups. The HoLEP group showed significantly shorter operation time (58.26 ± 20.11 min vs. 84.17 ± 36.80 min, P < 0.001), shorter catheterization time (5.37 ± 1.45 vs. 6.27 ± 1.47 days, P < 0.001), and reduced hospital stay (7.33 ± 3.12 vs. 13.61 ± 4.14 days, P < 0.001). Both groups demonstrated significant improvement in functional outcomes, but HoLEP had better international prostate symptom score, higher Qmax, (all P < 0.05). HoLEP had lower urinary tract irritation (22.62% vs. 42.86%) and erectile dysfunction (16.67% vs. 29.76%, both P < 0.05).
Conclusion:
HoLEP is a safe and effective alternative to TURP for BPH, offering advantages in perioperative safety and early recovery. It may be particularly beneficial in patients with large prostates or higher bleeding risk.
